The ATS Foundation presented Dr. Rounds with the 2019 Breathing for Life Award—the highest honor given to an ATS member for philanthropy—during the 11th annual ATS Foundation Research Program Benefit on Saturday evening at Union Station in Dallas.

Career advice, small-group learning, hands-on training, and networking comprised key elements of the ATS programming for Early Career Professionals on Friday and Saturday.

Taking charge of your own lung health was the theme of Saturday’s ATS Public Advisory Roundtable (PAR) Meet the Experts panel.

The second annual Respiratory Innovation Summit welcomed nearly 70 speakers and more than two dozen startup companies who previewed dozens of new therapies, drugs, devices, and diagnostics designed to treat respiratory disease.

When it comes to choosing the most appropriate treatment for a patient with sleep-disordered breathing, clinicians must make controversial choices.

Obesity has long been recognized as a significant risk factor for asthma. Nearly 60 percent of patients with severe asthma are obese, presenting a host of treatment challenges. In general, obese patients do not respond as well to conventional asthma therapies as lean patients. This leaves health care providers on the hunt for new options.

In classical pharmacology, drug-receptor interactions are considered under static conditions. A relatively new concept, mechanopharmacology, differs in that the normal mechanical environment of a tissue is a factor, with potentially significant impacts on function.